Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have earned a consensus rating of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.50.

Several brokerages have issued reports on CRSP. Piper Jaffray Companies began coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating on the stock. Oppenheimer began coverage on Crispr Therapeutics in a research note on Thursday, December 7th. They issued a “hold” rating on the stock. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. Finally, Barclays reissued a “buy” rating and issued a $29.00 price target on shares of Crispr Therapeutics in a research note on Friday, September 8th.

In other news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $18.98, for a total transaction of $21,114,225.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas Woiwode sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total value of $34,357.00. Following the sale, the director now owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,000,413 shares of company stock valued at $38,216,550. Corporate insiders own 39.98% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $193,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $235,000. Finally, Bank of New York Mellon Corp bought a new stake in Crispr Therapeutics during the third quarter worth $288,000. Hedge funds and other institutional investors own 24.52% of the company’s stock.

Crispr Therapeutics (NASDAQ CRSP) opened at $23.52 on Thursday. Crispr Therapeutics has a 12 month low of $11.63 and a 12 month high of $27.39. The company has a market capitalization of $964.78 and a P/E ratio of -73.50.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. During the same period last year, the firm posted ($2.77) earnings per share. Crispr Therapeutics’s quarterly revenue was up 54.2% compared to the same quarter last year. equities research analysts predict that Crispr Therapeutics will post -2.46 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/04/crispr-therapeutics-ag-crsp-given-consensus-rating-of-hold-by-brokerages.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.